2016•Unpublished venueRequires access

Optimal Therapy for Polycythemia Vera and Essential Thrombocythemia: A Different Perspective

Richard T. Silver, Hans Carl Hasselbalch

Abstract

Recent publications have de-emphasized the importance of recombinant interferon alpha (rIFNα) for the treatment of polycythemia vera (PV) or essential thrombocythemia (ET), favoring the use of phlebotomy and/or hydroxyurea. Here we express our reasons for the use of rIFNα early in the course of PV or ET in the absence of a phase 3 trial.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Polycythemia vera, Phlebotomy, Essential thrombocythemia, Medicine, Alpha interferon, Perspective (graphical), Anagrelide, Internal medicine